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Abstract 
An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed to rotavirus in 2010. About a 
third of these deaths occurred in India and Ethiopia. Public finance of rotavirus vaccination in these two countries could 
substantially decrease child mortality and also reduce rotavirus-related hospitalizations, prevent health-related 
impoverishment and bring significant cost savings to households. We use a methodology of ‘extended cost-effectiveness 
analysis’ (ECEA) to evaluate a hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. We 
measure program impact along four dimensions: 1) rotavirus deaths averted; 2) household expenditures averted; 3) 
financial risk protection afforded; 4) distributional consequences across the wealth strata of the country populations. In 
India and Ethiopia, the program would lead to a substantial decrease in rotavirus deaths, mainly among the poorer; it 
would reduce household expenditures across all income groups and it would effectively provide financial risk protection, 
mostly concentrated among the poorest. Potential indirect benefits of vaccination (herd immunity) would increase 
program benefits among all income groups, whereas potentially decreased vaccine efficacy among poorer households 
would reduce the equity benefits of the program. Our approach incorporates financial risk protection and distributional 
consequences into the systematic economic evaluation of vaccine policy, illustrated here with the case study of public 
finance for rotavirus vaccination. This enables selection of vaccine packages based on the quantitative inclusion of 
information on equity and on how much financial risk protection is being bought per dollar expenditure on vaccine 
policy, in addition to how much health is being bought. 
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Abstract 
 
Background 
An estimated 4% of global child deaths (approximately 300,000 deaths) were attributed 
to rotavirus in 2010. About a third of these deaths occurred in India and Ethiopia. Public 
finance of rotavirus vaccination in these two countries could substantially decrease child 
mortality and also reduce rotavirus-related hospitalizations, prevent health-related 
impoverishment and bring significant cost savings to households. 
 
Methods 
We use a methodology of ‘extended cost-effectiveness analysis’(ECEA) to evaluate a 
hypothetical publicly financed program for rotavirus vaccination in India and Ethiopia. 
We measure program impact along four dimensions: 1) rotavirus deaths averted; 2) 
household expenditures averted; 3) financial risk protection afforded; 4) distributional 
consequences across the wealth strata of the country populations. 
 
Results 
In India and Ethiopia, the program would lead to a substantial decrease in rotavirus 
deaths, mainly among the poorer; it would reduce household expenditures across all 
income groups and it would effectively provide financial risk protection, mostly 
concentrated among the poorest. Potential indirect benefits of vaccination (herd 
immunity) would increase program benefits among all income groups, whereas 
potentially decreased vaccine efficacy among poorer households would reduce the 
equity benefits of the program. 
 
Conclusions 
Our approach incorporates financial risk protection and distributional consequences 
into the systematic economic evaluation of vaccine policy, illustrated here with the case 
study of public finance for rotavirus vaccination. This enables selection of vaccine 
packages based on the quantitative inclusion of information on equity and on how much 
financial risk protection is being bought per dollar expenditure on vaccine policy, in 
addition to how much health is being bought. 
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1. Introduction 
About a third of global diarrhea-related deaths are attributed to rotavirus. In children 
younger than five years an estimated 4% deaths were the result of rotavirus-related 
diarrhea in 2010 [1] and [2]. The large majority of these deaths among under-fives were 
Highlights 
• Public finance of rotavirus vaccine could decrease child mortality and medical 
impoverishment. 
• In India/Ethiopia, it would decrease rotavirus deaths, mainly among the poorer. 
• In India/Ethiopia, it would prevent medical impoverishment, among the poorest. 
• This work incorporates financial risk protection into evaluation of vaccine policy. 
• Vaccine packages based on equity, financial protection, and health gains can be 
selected. 
in low-income populations of Africa and Asia [1] and [2]. Five countries (the Democratic 
Republic of the Congo, Ethiopia, India, Nigeria and Pakistan) accounted for more than 
half of all rotavirus deaths [1], [2] and [3]. 
The introduction of rotavirus vaccine into the vaccination schedule of lower income 
countries might lead to substantial reductions in child mortality and significantly reduce 
the number of rotavirus-related hospitalizations, as it has been observed in the (high- 
income) countries where implemented [4]. In sub-Saharan Africa and India, 90% of 
rotavirus-related hospitalizations occur among children under two years of age 
[5] and [6]. Though the efficacy of rotavirus vaccine, a standard two-dose regimen given 
at 6 and 12 weeks of age [7], has proven lower in the developing countries that are highly 
impacted by rotavirus [7] and [8],1 even a partially effective vaccine there could save 
many lives and bring substantial cost savings to households possibly preventing them 
from medical impoverishment. 
Rotavirus vaccination may be a very cost-effective intervention [9], [10], [11], [12], 
[13] and [14] which could save up to 2.5 million lives over the next 20 years in Global 
Alliance for  Vaccines and  Immunization(GAVI)-eligible countries[10].  Country-
specific benefits from rotavirus vaccination will depend on the specific burden of 
diarrhea, vaccine price and efficacy, and the targeting of the vaccination programs [9], 
[12] and [13]. Greater benefit should be expected in low-income countries, primarily 
because of high mortality levels. Within countries, greater benefit should be expected 
among the poorest populations who often have higher risks of death, reduced access to 
effective care, and bear significant economic costs due to disease treatment. 
Health interventions such as rotavirus vaccination, and by extension the policy levers 
that finance and deliver them, have distributional consequences across wealth strata of 
populations which they target. Early work has shown that universal measles vaccination 
coverage could substantially reduce income-related mortality differentials in high 
mortality settings [15]. More recently, Rheingans et al. [16] examined the cost- 
effectiveness of rotavirus vaccination per income group in selected GAVI-eligible 
countries, and found it most cost-effective to vaccinate in low-income populations.2 
Policy choices that affect vaccination coverage include public finance (PF) for routine 
administration of a specific vaccine, mass campaigns,3 and conditional cash transfers to 
encourage utilization [17]. PF policy of vaccine programs has some specific and positive 
consequences. First, PF increases uptake and leads to widespread health gains. 
Second, PF can reduce household expenditures on health care and prevent medical 
impoverishment. Finally, PF can have differential impact across a population by level of 
income[18]. 
In this paper, we apply a methodology of extended cost-effectiveness analysis (ECEA) 
[18] to evaluate the consequences of vaccine policy in each of the dimensions described 
above. We illustrate our approach with the case study of PF for rotavirus vaccination in 
two countries with substantial rotavirus burden, India and Ethiopia. Both countries have 
substantial rotavirus burden, yet differ significantly epidemiologically and economically. 
In order to make decisions on the introduction of new vaccines, Indian and Ethiopian 
policymakers need estimates of vaccination costs and outcomes, which differ across 
socio-economic groups. Distributional aspects have implications for decisions about 
where to invest first. The ECEA approach adds distributional consequences and 
financial risk protection (FRP) considerations to the decision criteria. It enables selection 
of vaccines based on quantitative inclusion of how much FRP is provided, as well as how 
much health is gained, per dollar expenditure on a policy [18]. 
 
2. Methods 
We evaluate PF for rotavirus vaccination at survey-reported levels of DPT2 (2nd dose of 
Diphteria-Pertussis-Tetanus vaccine)4 coverage in India and Ethiopia, drawing from 
Table 1. 
Parameters used for the base case scenario for the economic evaluation of public finance for rotavirus 
vaccination in India and Ethiopia. 
standard cost-effectiveness methods [21]. In each country, we follow a hypothetical 
cohort of 1,000,000 births over the first five years of life. Rotavirus-related mortality 
outcomes and household expenditures are estimated for this cohort. The five-year 
horizon captures all relevant effects with simplicity: one cohort is modeled, and under- 
five children constitute the population group in which outcomes mostly occur and for 
whom data (e.g. burden of disease) is available. We adopt a societal perspective and 
consider the vaccination costs borne by providers (e.g. governments), separated from 
the rotavirus-related expenditures borne by patients and their families. 
We estimate the level and distribution (across income groups) of the rotavirus deaths 
averted; the households’ expenditures (direct medical costs and transport costs) related 
to rotavirus treatment averted (‘private expenditures crowded out’) and the costs 
needed to sustain the program (vaccination costs borne by the government); and the 
financial risk protection afforded by the program measured by an imputed money-
metric value of ‘insurance’ provided, which we describe in detail in the supplementary 
data (Section 1.3). 
 
2.1. Data sources 
Values for all parameters are listed (Table 1). Before program introduction, individuals 
pay out of pocket for rotavirus treatment and the demand (utilization) and cost of this 
service vary by income group [20], [23], [24], [25], [26], [27], [28], [29], [30], [31] and [32]. 
Vaccine effectiveness is assumed to be 43% and 49% for India and Ethiopia, 
respectively (consistent with trial data from Bangladesh and Malawi [33] and [34]); 
vaccine price is $2.50 per dose as currently procured to the GAVI Alliance [35]. We 
assume the program would achieve a similar coverage across all income groups equal 
to mean DPT2 coverage reported from survey data [19] and [20],4 the incremental cost 
of vaccine administration to be $0.25 per dose based on the World Health Organization 
Global Immunization Vision and Strategy costing model [10] and [36]. 
 
 
 
 
 
Parameter 
 
India estimate 
Ethiopia 
estimate 
 
Reference(s) 
 
Rotavirus deaths 
(per 1000 live births) 
3.7 5.4 Based on [1], 
[2] and [22] 
 
Relative risk ratio of rotavirus mortality 2.8 2.9 Based on [16]  
(poorest to richest) {1.43, 1.22, {1.34, 1.23,   
{risk index, poorest to richest} 1.02, 0.82, 1.06, 0.91,   
 0.50} 0.46}   
Mean 5-year probability of inpatient visit for 3% 2% Based on  
rotavirus diarrhea {2, 4, 3, 2, 2} {2, 2, 2, 3, 3} [20], [23], [24], [25],  
{poorest to richest}   [26] and [27]  
Mean 5-year probability of outpatient visit 38% 26% Based on [19], [20],  
for rotavirus diarrhea {poorest to richest} {37, 37, 37, {18, 19, 27, [23], [28],  
 42, 39} 27, 38} [29] and [30]  
Vaccine effectiveness (%) 
(per 2-dose course) 
43 49 [33] and [34]  
Vaccination coverage (%) 
(per 2-dose course) 
76 52 Survey DPT2 
coverage [19] 
and [20] 
 
Mean out-of-pocket inpatient cost $82 $29 Based on [10], [23],  
for rotavirus diarrhea (2011 US$)a {63, 64, 73, {25, 25, 25, [31] and [32]  
{poorest to richest} 96, 115} 33, 38}   
Mean out-of-pocket outpatient cost $9 $9 Based on  
for rotavirus diarrhea (2011 US$)a {8, 8, 7, 9, 14} {8, 8, 9, 11, [10], [23],  
{poorest to richest}  10} [31] and [32]  
Vaccine price (per 2-dose course) $5.0 $5.0 [35]  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DPT2, 2nd dose of Diphteria-Pertussis-Tetanus vaccine. 
 
a Includes both direct medical costs and transport costs disbursed out of pocket. 
 
b India's projected GDP per capita for 2013 is above $1520, hence, if India benefits from GAVI co- 
financing, the GAVI-subsidized price would start at 20% of the vaccine projected price (20% of 
$5.00 = $1.00) and increase gradually (by $1.00 increments) over four years to reach the projected 
price. 
c The distribution of borrowing or selling assets among income groups is extracted from [46], and the 
ratio between poorest and richest households borrowing or selling assets is assumed to be 2.5. 
Ethiopians are assumed to borrow the same amount of money as Indians. 
 
Table options 
 
Vaccine price with GAVI subsidy 
(per 2-dose course) 
b $0.4 [35]  
Incremental vaccination system cost (per 2- 
dose course) 
$0.5 $0.5 [10] and [36]  
Gross domestic product (GDP) per capita 
(2011 current US$) 
$1489 $374 [32]  
Gini index 33 30 [32]  
Percent of households borrowing for 
rotavirus inpatient visit 
(mean amount borrowed) 
31.7%c ($24) N/A [23]  
Percent of households selling assets for 
rotavirus inpatient visit 
(mean amount obtained) 
3.8%c ($2) N/A [23]  
Percent of households borrowing for 
outpatient visit for rotavirus 
(mean amount borrowed) 
7.9%c ($2) N/A [23]  
Percent of households selling assets for 
outpatient visit for rotavirus 
(mean amount obtained) 
0.3%c ($0) N/A [23]  
Utility function as a function of individual 
income y 
y1−r/(1−r); 
r = 3 
y1−r/(1−r); 
r = 3 
Based on [18] 
(Supplementary data)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2. Rotavirus deaths averted 
The model follows a birth cohort of 1,000,000 individuals over five years and uses an 
indicator of relative rotavirus mortality (‘risk index’) varying by income group in order to 
quantify the reduction in under-five mortality due to rotavirus, in each income group, an 
approach which was implemented elsewhere [16]. Before the vaccination program, the 
rotavirus burden of disease is distributed across income groups, based on the risk index 
specified by income group (Table 1). The approach is static; in the case of rotavirus, 
vaccination may provide some protection to unvaccinated individuals due to herd 
immunity, which has been documented in a few (high-income) countries [37], 
[38] and [39]. In section 3.2.3, herd effects are imputed into our model in order to 
estimate possible additional benefits of indirect  protection due to vaccination. 
 
2.3. Consequences for household expenditures and government costs 
From the patient perspective, we estimate (by income group) the amount of household 
expenditures averted for rotavirus treatment following program introduction.  They 
represent cost savings from the household perspective. In each country, for the 
hypothetical cohort followed over five years, rotavirus-related expenditures borne by 
families, with and without vaccination, are estimated and depend on five-year 
probabilities of outpatient/inpatient visits for rotavirus and household expenditures for 
rotavirus-related outpatient/inpatient visits. Direct medical costs from 
outpatient/inpatient visits, and transport costs are included. Waiting time and travel time 
are not included. Informal medical treatment costs, and earning and productivity losses 
are excluded. 
 
From the provider perspective, we estimate the total costs of the vaccination program to 
the government, depending on vaccine price and incremental administrative costs, and 
vaccination coverage. 
 
2.4. Financial risk protection afforded 
We quantify the FRP benefits brought to households by the program in monetary terms. 
For this purpose, we develop a money-metric value of FRP, in applying a standard utility- 
based model where risk-averse individuals value protection from the risk of uncertain 
events [18], [40] and [41]. First, before the vaccination program is introduced, in the 
uncertain scenario, we estimate the expected value of the individual's income associated 
with the eventuality (uncertainty) of expenditures related to rotavirus with 
given probability and cost. Second, we use a utility function that depends on the 
individual's income and relative risk aversion (constant relative  risk aversion utility 
function [42] and [43]). Using this utility-based framework, in the certain scenario, we 
estimate the income the individual is willing to have in order to have the outcome certain 
(named ‘certainty equivalent’). Finally, the difference between the expected value of the 
individual's income and the income the individual is willing to have in order to have the 
outcome certain (i.e. the ‘risk premium’) yields a money-metric value of FRP provided by 
the program (by income group). 
Complete details are given in the supplementary data (section 1). All analyses were 
conducted using  Mathematica[44]. 
 
3. Results 
We present our results for the base case scenario using standard data and four 
additional scenarios that consider i) changes in the vaccine price (3.2.1); ii) 
consequences of borrowing and asset selling (3.2.2); iii) addition of indirect benefits of 
vaccination (3.2.3); and iv) variations in vaccine efficacy according to income group 
(3.2.4). These extensions capture four important economic and epidemiological 
considerations that can, under different  aspects, significantly impact the base case 
findings. We thus implement a scenario analysis to explore variations. 
 
3.1. Base case scenario 
For the base case scenario (Fig. 1), 32,000 lives would be saved in India (1200 per 
million births) representing 32% of all rotavirus deaths and 3700 lives in Ethiopia (1400 
per million births) representing 26% of all rotavirus deaths. In India and Ethiopia, more 
lives would be saved among the bottom income quintile compared to the top income 
quintile (29% and 27% of benefits accrue to the bottom income quintile in India and 
Ethiopia). In India and Ethiopia, total household expenditures averted per million infants 
vaccinated would be $1,800,000 and $800,000, and the bottom two income quintiles 
would account for about 34% and 25% of all household expenditures averted. Total 
vaccination costs (assuming a cost of $5.50 per child vaccinated) incurred by the 
government would amount to $4,200,000 and $2,900,000. Total FRP (for 1,000,000 
households) would be about $16,000 and $8000. The largest FRP value would be felt by 
the bottom income quintile in India (33% of total FRP) and Ethiopia (27%). A steeper 
gradient for rotavirus treatment utilization between the poorer and richer in Ethiopia, 
combined with a substantially lower average income ($374 vs. $1489 per capita), 
explains the trend of the FRP value as a function of income in Ethiopia. 
 
 
 
 
 
3.2. Extensions to the base case scenario 
3.2.1. Changes in the vaccine price 
The GAVI Alliance offers a co-financing mechanism for low-income countries on a 
sliding scale according to their income level [35]. Specifically, countries with a gross 
domestic product (GDP) per capita lower than $1005 per annum can obtain a GAVI- 
subsidized vaccine price of $0.20 per dose: this is the case of Ethiopia. Countries with a 
GDP per capita above $1520 which have just ‘graduated’ from GAVI may pay 20% of the 
vaccine price the first year with a gradual increase over the following four years [35]. 
We explore how changes in vaccine price (which can reflect expected transitions when 
governments face market prices) may affect the results in terms of health gains and FRP 
afforded by the program. The number of deaths averted and FRP afforded per $1 million 
spent was examined among income groups for a few vaccine prices (Fig. 2). In each 
country, as vaccine price decreases, deaths averted and FRP afforded increase for any 
income group. In India, for a vaccine price of $2.00, a stated target price for vaccines 
currently being developed in India [45], $1,000,000 spent by the program would buy 
about $8000 of FRP and avert 630 deaths of which 33% of FRP and 29% of deaths 
averted would accrue among the bottom income quintile. In Ethiopia, for a vaccine price 
of $0.40, $1,000,000 would buy about $17,000 of FRP saving 3600 lives of which 27% of 
FRP and 27% of lives saved would accrue among the bottom income quintile. With 
vaccine prices of $2.00 and $0.40 in India and Ethiopia, for any income group, the  
deaths averted are larger in Ethiopia; however, the FRP afforded in India's bottom 
income quintile is similar to Ethiopia's second and third income quintiles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. 
Level and distribution of benefits for a 1,000,000 birth cohort followed over 5 years, with public finance 
for rotavirus vaccination at DPT2 current coverage, India and Ethiopia: Rotavirus deaths averted (a), 
household expenditures averted (b), financial risk protection afforded (c). 
Figure options 
 
 
 
3.2.2. Borrowing and asset selling 
When faced with costly medical treatment, the poor use coping mechanisms such as 
borrowing from relatives and peers or selling assets [46]. We assume that borrowing or 
asset selling would concern individuals in all income groups, and that it would occur over 
a 10-year period where people would take a loan with a given interest rate (details are 
provided in the supplementary data, Section 2).5 When a loan is started, the borrower's 
debt increases. Borrowing increases the expenditures the households would pay in the 
absence of the program. Hence, with the inclusion of borrowing in the analysis, the 
household expenditures averted and the FRP afforded increase. In particular, the FRP 
afforded increases as the borrowing interest rate increases (Fig. 3). Using a 40% annual 
interest rate, as reported in parts of India [47], we find substantially larger FRP values: 
$26,000 for India, 38% among the bottom income quintile; $17,000 for Ethiopia, 35% 
among the bottom income quintile. At a vaccine price of $2.00, the FRP afforded would 
represent 0.9% of total program costs ($1,900,000) in India. At a vaccine price of $0.40, 
the FRP afforded would represent 3.6% of total program costs ($500,000) in Ethiopia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3. 
Financial risk protection afforded (with borrowing included) for a 1,000,000 birth cohort followed over 5 
years, with public finance for rotavirus vaccination at current DPT2 coverage, as a function of individual 
borrowing interest rate, India and Ethiopia. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2. 
Deaths averted and financial risk protection afforded over 5 years with the introduction of public finance 
for rotavirus vaccination at DPT2 current coverage, per $1,000,000 spent, as a function of vaccine price, 
India and Ethiopia. Income quintiles: I = poorest, II = poorer, III = middle, IV = richer, V = richest. 
Figure options 
 
 
 
3.2.3. Indirect benefits of vaccination 
Rotavirus vaccination may provide protection to unvaccinated individuals due to herd 
immunity, although evidence on herd effects from vaccination comes mostly from higher 
income countries where vaccine efficacy is high [37], [38] and [39]. If herd effects in high- 
income country settings were replicated in developing country settings, where efficacy 
and coverage are lower, a vaccine with indirect protection could provide greater benefits 
than expected solely based on direct efficacy. In order to estimate the program benefits 
including this potential indirect protection, additional benefits of 1/3 are imputed to our 
results, based on published reports [37], [38] and [39]. Expectedly, indirect vaccination 
effects may increase all benefits of the program by 1/3. For India, about 1600 deaths, 
29% of which are among the bottom income quintile, would be averted; about 
$2,400,000 household expenditures, 34%  among  the bottom two income quintiles, 
would be averted; $21,000 FRP, 33% among the bottom income quintile, would be 
afforded, about 1.1% of total program costs. For Ethiopia, 1900 deaths, 27% among the 
bottom income equintile, would be averted; about$1,100,000 household expenditures, 
25% among the bottom two income quintiles, would be averted; about $11,000 FRP, 
27% among the bottom income quintile, would be afforded, about 2.2% of total program 
costs. 
 
3.2.4. Vaccine efficacy varies by income group 
We assume vaccine efficacy varies by income group: efficacy increases as individual 
income increases. This is consistent with trial data where lower/higher efficacy was 
demonstrated in lower/higher income countries [33], [34], [48], [49] and [50]. In sub- 
Saharan Africa, the Rotarix trial [34] was conducted in two countries and three sites (two 
in South Africa and one in Malawi). In South Africa, the two sites were Soweto (middle 
class) and rural Pretoria (very poor): unpublished results demonstrated lower efficacy in 
rural Pretoria (personal communication), and Malawi had lowest efficacy. Live oral 
vaccine efficacy may differ in high-income vs. low-income populations due to 
immunological factors such as different titers of breast-milk antibodies [7] and [8]. 
Specifically, we observe a linear-log relationship between efficacy (Veff) and GDP per 
capita [8] (Fig. 4): 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4. 
Country point estimates of rotavirus vaccine efficacy as a function of country gross domestic product 
 
 Veff b0+b1ln(GDP) (1) 
 
 
 
 
Figure options 
 
 
 
We find high goodness of fit (R2 = 0.81), which validates the use of model (1) for our 
analysis. The coefficient on ln(GDP) implies that a 10% change in GDP per capita is 
associated with a 1.2% increase in vaccine efficacy. Using regression results from (1), 
we derive the following vaccine efficacies (from poorest to richest): {34, 38, 41, 46, 52}% 
for India and {41, 45, 48, 52, 58}% for Ethiopia. 
 
Based upon these assumptions, the program benefits change (Fig. 5). Lives saved 
would decrease to 1100 for India and 1300 for Ethiopia, and be less concentrated among 
the bottom income quintile: 24% (270 deaths) for India; 23% (310 deaths) for Ethiopia. 
The household expenditures averted would remain of about $1,900,000 and $800,000, 
for India and Ethiopia. However, the bottom two quintiles household expenditures 
averted would now decrease to about 28% ($500,000) and 21% ($150,000). Total FRP 
afforded would decrease to $15,000 and $8000. The largest FRP would still be among 
the bottom income quintile in India (27%), but the gradient among income groups be 
diminished in India and Ethiopia. 
 
 
 
4. Discussion 
We evaluated the level and distribution of health and FRP benefits of PF for a rotavirus 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 5. 
Level and distribution of benefits for a 1,000,000 birth cohort followed over 5 years, with public finance  
for rotavirus vaccination at DPT2 current coverage, with varying vaccine efficacy among income groups, 
India and Ethiopia: Rotavirus deaths averted (a), household expenditures averted (b), financial risk 
protection afforded (c). 
Figure options 
 
 
 
 
(GDP) per capita. Adapted from Nelson and Glass (2010) [8]. Veff b0 + b1 ln(GDP), where b0 = −30.2 
(Standard Error = 16.5, P = 0.10), b1 = 11.8 (S.E. = 1.9, P < 0.001). 
Figure options 
vaccination program in India and Ethiopia. We demonstrated that such program would 
lead to substantial reductions in rotavirus deaths, principally concentrated among the 
poorer and would avert household expenditures across all income groups. The program 
would provide FRP, mostly concentrated among the poorest. Comparatively, it would 
lead to a higher rate of rotavirus deaths averted in Ethiopia, as estimated mortality is 
higher there, and to higher FRP in India as Indians’ healthcare utilization and household 
expenditures for rotavirus treatment are larger (Fig. 1). 
Our results point to the importance of vaccine pricing, specifically GAVI co-financing. 
Ethiopia would face a GAVI-subsidized price ($0.20 per vaccine dose), and see larger 
health and FRP gains, per $ spent. India, being ineligible for GAVI support, would likely 
face a price of $1.00 per dose, see substantial, but smaller health and FRP gains per $ 
spent (Fig. 2). A steep rise in vaccine price, say after GAVI support expires, would 
dramatically alter the benefits: this is critical for low-income countries. Furthermore, we 
show that potential indirect benefits from vaccination may save additional lives and 
increase FRP, which points to data needs on herd effects of rotavirus vaccination in 
lower income settings. Herd immunity may indirectly ‘reach out’ to marginalized 
populations overlooked by health systems. It may therefore enhance equity, especially 
when decreased vaccine efficacy diminishes program benefits among the poorest (Fig. 
5). 
The analysis presents several limitations. First, settings are heterogeneous in income 
but also geographically (e.g. rural vs. urban) and epidemiologically. Heterogeneities 
entail economic differentials in costs (e.g. program costs) and quality (e.g. vaccine cold 
chain may be harder to maintain in certain areas), as well as epidemiological differentials 
in rotavirus mortality by age, for example. Notably, quality can differ substantially among 
sub-populations, and PF provision may enhance quality by crowding out bad treatment 
options (e.g. ineffective antibiotics). Dynamic modeling capturing herd effects and 
seasonality [51] and [52] could address some of these heterogeneities in spite of a 
critical lack of data, and also remedy the likely underestimation of health and FRP 
benefits without inclusion of herd immunity. In lieu of a dynamic model, using a ‘back of 
the envelope’ approach, herd effects were imputed into our model in order to estimate 
possible additional benefits of indirect protection due to vaccination. Herd effects may 
also differ by income quintiles as disease transmission differs among socio-economic 
groups. Likewise, when available, data on vaccine efficacy by population sub-groups in 
Ethiopia and India would be better than estimates based on country differences. Second, 
‘universal coverage’ was not addressed. Universal coverage may be considered if 
decision makers switch policy in order to extend coverage beyond levels currently 
achieved by health systems. For example, one could replace the use of routine 
vaccination by the use of mass campaigns or conditional cash transfers, at a certain 
point. Universal coverage may therefore be possible if the appropriate combination of 
policy levers and delivery platforms is implemented. Future work could consider long- 
term horizons targeting multiple birth cohorts. This would help policymakers understand 
how program benefits evolve, as vaccine price gradually changes over time. In addition, 
examining vaccine price and delivery by private entities and comparing with public 
provision would be valuable. Finally, future FRP measures would include productivity 
and earning losses associated with accompanying sick children to care, and PF of 
rotavirus vaccination would also be compared with scaling up of diarrhea treatment (e.g. 
oral rehydration therapy). 
 
5. Conclusions 
Using an ECEA approach [18], this paper presented a methodology for incorporating 
FRP and distributional consequences into the systematic economic evaluation of 
vaccine policy, illustrated here with the case study of public finance for rotavirus 
vaccination. In line with recently published works on the wider economic benefits of 
vaccination [53], [54], [55] and [56], our ECEA approach goes beyond traditional cost- 
effectiveness analysis in assessing consequences in three additional dimensions: 
protection against financial risks, direct household financial implications and 
distributional consequences across population strata. This enables selection of 
vaccine packages based on quantitative inclusion of information of how much FRP is 
being bought, as well as how much health is being bought with, say a million dollar 
expenditure on a vaccine policy (Fig. 2). The framework introduced can be applied to 
the comparative economic evaluation of a wide range of vaccines (e.g. pneumococcal, 
human papillomavirus) and policy levers such as conditional cash transfers or mass 
campaigns, in order to select, potentially, the vaccines to be included in vaccination 
schedules. 
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1 Many hypotheses have been suggested to explain this difference in efficacy of live 
oral rotavirus vaccines between developing and developed countries, including 
breastfeeding practices,  micronutrient malnutrition,  or differences in rotavirus 
epidemiology [7]. This difference is most likely linked to the levels of antibody 
transferred from the mother to the infant which can inhibit the infant immune response 
to the vaccine. 
2 Given the same vaccination cost per income group. 
3 Mass campaigns are commonly implemented for vaccines such as measles or polio 
but may not be appropriate for rotavirus vaccine which has to be given within a very 
specific time schedule. 
4 Survey-reported DPT2 coverage [19] and [20] was used to estimate the fraction of 
newborns that would receive the two doses of rotavirus vaccine. DPT2 coverage is 
meant to capture a realistic country health system capacity and to represent 
achievable vaccine coverage. DPT2 coverage was 76% in India in 2008 [19] and 52% 
in Ethiopia in 2011 [20]. 
5 10- year is chosen for illustration purposes; the borrowing period may be much 
shorter as rotavirus diarrhea represents an acute event. 
 
   
